Harold Bays

2 weeks ago | healio.com | Andrew Rhoades |Harold Bays

NATIONAL HARBOR, Md. —In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk on anti-obesity medications in the pipeline. There is an “unbelievable number of anti-obesity drugs in development,” including GLP-1 receptor agonists with other incretins and appetite suppressants, Bays, chief science officer and president-elect of the Obesity Medicine Association, told Healio.

2 months ago | uscjournal.com | Harold Bays |Naveed Sattar |Gurleen Kaur |Saman Nematollahi

Average (ratings) Abstract With the dawn of advanced technological and digital resources, medical education has changed. Learners are now able to learn, share, and communicate medical knowledge through online discussion forums, blogs, videos, podcasts, infographics, virtual communities, social media platforms, and collaborative author groups. Navigating these digital education modalities can be challenging, with each platform presenting unique challenges and opportunities.

Nov 27, 2024 | radcliffecvrm.com | Harold Bays |Lydia Alexander |Harriette Van Spall

Video Published: Views: 36 Likes: 0 Average (ratings) AHA Conference 2024 - Outcomes of SELECT show that semaglutide treatment in obese or overweight patients with prior history of coronary artery bypass graft (CABG) surgery reduces the risk of cardiovascular events. Dr Subodh Verma (University of Toronto, Toronto, CA) joins us onsite at AHA Conference to discuss the findings from SELECT (NCT03574597).

Nov 18, 2024 | radcliffecvrm.com | Harriette Van Spall |Harold Bays |Mikhail Kosiborod

AHA Conference 2024  — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile. Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD). The FLOW trial (NCT03819153) is designed to assess the effect of semaglutide as compared to placebo in patients with chronic kidney disease and type 2 diabetes.

Nov 8, 2024 | uscjournal.com | Harold Bays |Kadijah Porter |Brototo Deb |Andriy Katyukha

Vast disparities in cardiovascular morbidity and mortality exist, which partly stem from the underrepresentation of minoritized individuals in clinical research and clinical trials. These disparities encompass sociodemographic factors, such as race, ethnicity, and income status. Another significant source of disparity is biological sex, which is often misconstrued as gender in cardiovascular research.